Register Login

Atea Pharmaceuticals Inc (AVIR)

(10% Negative) Atea Pharmaceuticals, Inc. (AVIR) Announces Delay in priorities Trials for serious viral diseases Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 8, 2026, 2:07 p.m.

    📋 Atea Pharmaceuticals, Inc. (AVIR) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 09:05:09

    Event Type: Clinical Trial Update

    Event Details:

    Atea Pharmaceuticals Inc (AVIR) Announces Clinical Trial Update Atea Pharmaceuticals Inc (AVIR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: priorities, investments
    • Diseases/Conditions: serious viral diseases
    • Clinical Stage: Phase 3 program, Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: C-FORWARD Trial
    • Updated Timeline: December 31, 2025
      • targeting HEV, for which no approved DAA therapies currently exist. Leveraging Atea’s proprietary nucleos(t)ide prodrug platform and drug discovery expertise, Atea has selected as the lead product candidate AT-587, a nucleotide analog. AT-587 has demonstrated potent nanomolar antiviral activity against HEV in vitro. In in vivo single-dose nonclinical pharmacokinetic studies, AT-587 achieved high plasma concentrations of the surrogate of the active intracellular triphosphate metabolite across all species, including rats and monkeys. In vitro toxicology, pharmacology and DMPK data present a favorable preclinical profile for AT-587. Additional first-in-human enabling studies are ongoing and Atea anticipates initiating a Phase 1 study in mid-2026

    🔬 Clinical Development Pipeline (Atea Pharmaceuticals, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) DRUG Phase PHASE1 Healthy Volunteer Study ClinicalTrials.gov
    Bemnifosbuvir/Ruzasvir (BEM/RZR) DRUG Phase PHASE1 Healthy Volunteer Study ClinicalTrials.gov
    Placebo OTHER Phase PHASE1 Healthy Adult Participants ClinicalTrials.gov
    GSM-779690T DRUG Phase PHASE1 Healthy Adult Participants ClinicalTrials.gov
    Methadone +BEM/RZR DRUG Phase PHASE1 Healthy Volunteer Study ClinicalTrials.gov
    Buprenorphine/Naloxone + BEM/RZR DRUG Phase PHASE1 Healthy Volunteer Study ClinicalTrials.gov
    ASTX727 DRUG Phase PHASE1 Neurological Cancer ClinicalTrials.gov
    Ethinyl Estradioll/Levonorgestrel (EE/LNG) DRUG Phase PHASE1 Healthy Volunteer Study ClinicalTrials.gov
    Sofosbuvir-Velpatasvir (SOF/VEL) DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION ClinicalTrials.gov
    Bemnifosbuvir-Ruzasvir (BEM/RZR) DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION ClinicalTrials.gov
    Placebo ointment DRUG Phase PHASE2 Angiofibroma of Face ClinicalTrials.gov
    Sirolimus 0.4% DRUG Phase PHASE2 Angiofibroma of Face ClinicalTrials.gov
    Sirolimus 0.2% DRUG Phase PHASE2 Angiofibroma of Face ClinicalTrials.gov
    Sofosbuvir-Velpatasvir DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION ClinicalTrials.gov
    Bemnifosbuvir-Ruzasvir DRUG Phase PHASE3 HEPATITIS C VIRUS CHRONIC INFECTION ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Ruzasvir DRUG Phase PHASE2 Chronic Hepatitis C Virus ClinicalTrials.gov
    Bemnifosbuvir DRUG Phase PHASE2 Chronic Hepatitis C Virus ClinicalTrials.gov
    Donor Lymphocyte Infusion DRUG Phase PHASE2 Allogeneic Stem Cell Transplantation ClinicalTrials.gov
    Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination DRUG Phase PHASE1 Healthy Volunteer Study ClinicalTrials.gov
    Decitabine and Cedazuridine DRUG Phase PHASE1 Chronic Myelomonocytic Leukemia ClinicalTrials.gov
    AO-252 DRUG Phase PHASE1 Solid Tumor Malignancies ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Atea Pharmaceuticals Inc
    • CIK: 0001593899
    • Ticker Symbol: AVIR
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories